MX2024002824A - Conjugados antivirales de peptido de coronavirus 2 del sindrome respiratorio agudo severo (sars-cov-2)-colesterol estructuralmente engrapados y usos de los mismos. - Google Patents
Conjugados antivirales de peptido de coronavirus 2 del sindrome respiratorio agudo severo (sars-cov-2)-colesterol estructuralmente engrapados y usos de los mismos.Info
- Publication number
- MX2024002824A MX2024002824A MX2024002824A MX2024002824A MX2024002824A MX 2024002824 A MX2024002824 A MX 2024002824A MX 2024002824 A MX2024002824 A MX 2024002824A MX 2024002824 A MX2024002824 A MX 2024002824A MX 2024002824 A MX2024002824 A MX 2024002824A
- Authority
- MX
- Mexico
- Prior art keywords
- cov
- sars
- stapled
- structurally
- acute respiratory
- Prior art date
Links
- 241001678559 COVID-19 virus Species 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 230000000840 anti-viral effect Effects 0.000 title 1
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract 2
- QGVQZRDQPDLHHV-DPAQBDIFSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-3-thiol Chemical group C1C=C2C[C@@H](S)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 QGVQZRDQPDLHHV-DPAQBDIFSA-N 0.000 abstract 1
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Botany (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163241722P | 2021-09-08 | 2021-09-08 | |
| PCT/US2022/076114 WO2023039474A1 (en) | 2021-09-08 | 2022-09-08 | Antiviral structurally-stapled sars-cov-2 peptide- cholesterol conjugates and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024002824A true MX2024002824A (es) | 2024-06-28 |
Family
ID=83594405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002824A MX2024002824A (es) | 2021-09-08 | 2022-09-08 | Conjugados antivirales de peptido de coronavirus 2 del sindrome respiratorio agudo severo (sars-cov-2)-colesterol estructuralmente engrapados y usos de los mismos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250084128A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4399220A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024533273A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240052851A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118401542A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2022341116A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3231587A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL311151A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024002824A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023039474A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120958134A (zh) * | 2023-04-12 | 2025-11-14 | 西湖大学 | 用于抑制冠状病毒的融合脂肽 |
| WO2025147479A1 (en) * | 2024-01-04 | 2025-07-10 | Merck Sharp & Dohme Llc | Viral fusion inhibitors |
| WO2025235945A1 (en) * | 2024-05-10 | 2025-11-13 | Red Queen Therapeutics, Inc. | Methods of treating viral infections using a fusion inhibitor |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US20020064546A1 (en) | 1996-09-13 | 2002-05-30 | J. Milton Harris | Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor |
| ES2211033T3 (es) | 1998-01-07 | 2004-07-01 | Debio Recherche Pharmaceutique S.A. | Acrilatos de polietilenglicol heterobifuncionales degradables y geles y conjugados derivados de dichos acrilatos. |
| US6348558B1 (en) | 1999-12-10 | 2002-02-19 | Shearwater Corporation | Hydrolytically degradable polymers and hydrogels made therefrom |
| BR0001870B1 (pt) | 2000-05-29 | 2014-02-25 | Peptídeo, processo de obtenção de peptídeo, formulação compreendendo peptídeo, método de prevenção de crescimento de parasitas, fungos e bactérias, método para inativar a endotoxina de bactérias gram-negativas | |
| CN1223605C (zh) * | 2003-05-16 | 2005-10-19 | 中国科学院微生物研究所 | 抑制sars冠状病毒的多肽药物及其衍生物和其应用 |
| EP1680443B9 (en) | 2003-11-05 | 2014-09-03 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides and uses thereof |
| EP2208061B1 (en) | 2007-09-26 | 2017-11-08 | Dana Farber Cancer Institute | Methods and compositions for modulating bcl-2 family polypeptides |
| WO2010060112A1 (en) | 2008-11-24 | 2010-05-27 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles with improved properties |
| EP3549951A3 (en) | 2008-12-09 | 2019-11-20 | Dana Farber Cancer Institute, Inc. | Methods and compositions for specific modulation of mcl-1 |
| EP3698811A1 (en) | 2009-06-18 | 2020-08-26 | Dana Farber Cancer Institute, Inc. | Structured viral peptide compositions and methods of use |
| CA3010713A1 (en) * | 2016-01-07 | 2017-07-13 | Navigen, Inc. | D-peptide inhibitors of hiv entry and methods of use |
| US20190048038A1 (en) | 2016-02-23 | 2019-02-14 | Dana-Farber Cancer Institute, Inc. | Method for generating cell-penetrating stapled peptides that lack nonspecific membrane-lytic properties for therapeutic targeting |
| EP4267166A4 (en) * | 2020-12-22 | 2024-11-27 | The University of Chicago | Blockade of sars-cov-2 infection using hydrocarbon stapled peptides |
-
2022
- 2022-09-08 MX MX2024002824A patent/MX2024002824A/es unknown
- 2022-09-08 CN CN202280074123.2A patent/CN118401542A/zh active Pending
- 2022-09-08 IL IL311151A patent/IL311151A/en unknown
- 2022-09-08 EP EP22785887.5A patent/EP4399220A1/en active Pending
- 2022-09-08 WO PCT/US2022/076114 patent/WO2023039474A1/en not_active Ceased
- 2022-09-08 US US18/689,565 patent/US20250084128A1/en active Pending
- 2022-09-08 JP JP2024514660A patent/JP2024533273A/ja active Pending
- 2022-09-08 KR KR1020247011460A patent/KR20240052851A/ko active Pending
- 2022-09-08 AU AU2022341116A patent/AU2022341116A1/en active Pending
- 2022-09-08 CA CA3231587A patent/CA3231587A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4399220A1 (en) | 2024-07-17 |
| JP2024533273A (ja) | 2024-09-12 |
| US20250084128A1 (en) | 2025-03-13 |
| KR20240052851A (ko) | 2024-04-23 |
| CA3231587A1 (en) | 2023-03-16 |
| WO2023039474A1 (en) | 2023-03-16 |
| IL311151A (en) | 2024-04-01 |
| CN118401542A (zh) | 2024-07-26 |
| AU2022341116A1 (en) | 2024-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021015318A2 (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| MX2021013679A (es) | Compuestos antivirales que contienen nitrilo. | |
| MD20220043A2 (ro) | Compuşi foarte activi împotriva COVID-19 | |
| MX2022000037A (es) | Enlazadores hidrofilicos para conjugados de peptidos multivalentes. | |
| BR112021025655A2 (pt) | Inibidores da replicação do vírus da imunodeficiência humana | |
| MX9403380A (es) | Inhibidores de proteasa de vih utiles para el tratamiento de sida. | |
| PE20161325A1 (es) | L-asparaginasa tratada con peg | |
| CY1115289T1 (el) | Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη | |
| CY1108065T1 (el) | Χρηση βοτουλινικης τοξινης για την παρασκευη ενος φαρμακου για περιφερικη χορηγηση για θεραπεια πονου που δεν σχετιζεται με μυϊκο σπασιμο ή πονοκεφαλο | |
| MX2024002581A (es) | Lou064 para el tratamiento de la esclerosis multiple. | |
| CO2024006727A2 (es) | Compuestos y composiciones macrocíclicos, y métodos para preparar y utilizar los mismos | |
| WO2021178714A3 (en) | ANTIVIRAL STRUCTURALLY-STABILIZED SARS-CoV-2 PEPTIDES AND USES THEREOF | |
| BR112023021510A2 (pt) | Métodos de tratamento de estenoses esofágicas | |
| CO2022015428A2 (es) | Compuesto de oxofenilarsina deuterada y uso del mismo | |
| BR112022022599A2 (pt) | Métodos de tratamento de covid-19 usando bardoxolona metil ou análogos da mesma | |
| MX2022009776A (es) | Tratamiento de la colangitis biliar primaria con elafibranor. | |
| MX2020004930A (es) | Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido). | |
| MX2025008259A (es) | Inhibidores de prmt5-mta | |
| CO2025018532A2 (es) | Un método para el tratamiento de tumores sólidos con un conjugado anticuerpo-fármaco dirigido a claudina 18.2 | |
| CO2023017669A2 (es) | Terapia combinada anti-vhc ventajosa | |
| CO4130200A1 (es) | Inhibidores de proteasa del hiv utiles en el tratamiento del sida | |
| MX2022012115A (es) | Composicion farmaceutica para prevenir o tratar la mucositis inducida por radioterapia, quimioterapia o combinacion de las mismas, que comprende derivados de glp-2 o conjugado de accion prolongada de los mismos. | |
| CL2025003690A1 (es) | Compuestos anti-vih. | |
| MX2025002228A (es) | Metodos para el tratamiento o la profilaxis de la endometriosis | |
| MX2022005448A (es) | Método de tratamiento de queratodermia palmoplantar. |